DMKC Advisory Services LLC Acquires New Stake in Becton, Dickinson and Company $BDX

DMKC Advisory Services LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,280 shares of the medical instruments supplier’s stock, valued at approximately $774,000.

Other institutional investors also recently bought and sold shares of the company. Saudi Central Bank acquired a new position in shares of Becton, Dickinson and Company in the first quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new position in Becton, Dickinson and Company in the 1st quarter valued at approximately $27,000. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the first quarter worth $29,000. Cornerstone Planning Group LLC increased its position in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at $31,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on the company. Argus boosted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Piper Sandler reiterated a “neutral” rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Morgan Stanley boosted their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Stock Up 2.0%

Shares of NYSE:BDX opened at $190.90 on Thursday. The firm has a 50 day simple moving average of $188.71 and a 200-day simple moving average of $188.20. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $54.72 billion, a PE ratio of 34.33, a P/E/G ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same period last year, the firm posted $3.50 EPS. The company’s revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a dividend of $1.04 per share. The ex-dividend date was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is 74.82%.

Insider Activity

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock valued at $562,036 over the last three months. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.